C Langebrake

Summary

Country: Germany

Publications

  1. ncbi Minimising the long-term adverse effects of childhood leukaemia therapy
    Claudia Langebrake
    Department of Paediatric Haematology and Oncology, University Children s Hospital Munster, Munster, Germany
    Drug Saf 25:1057-77. 2002
  2. ncbi Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring
    Claudia Langebrake
    Department of Pediatric Hematology and Oncology, University Children s Hospital Munster, Munster, Germany
    Cytometry B Clin Cytom 63:1-9. 2005
  3. ncbi Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts
    C Langebrake
    University Children s Hospital Muenster, Department of Pediatric Hematology and Oncology, 48129 Muenster
    Klin Padiatr 217:126-34. 2005
  4. ncbi Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11)
    J Neudenberger
    Department of Paediatric Haematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
    Br J Haematol 133:337-44. 2006
  5. ncbi [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]
    D Reinhardt
    Pädiatrische Hämatologie Onkologie, Universitat Munster, Germany
    Klin Padiatr 214:179-87. 2002
  6. ncbi Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group
    Claudia Langebrake
    Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
    J Clin Oncol 24:3686-92. 2006
  7. ncbi Preanalytical mRNA stabilization of whole bone marrow samples
    Claudia Langebrake
    Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
    Clin Chem 53:587-93. 2007
  8. ncbi Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
    Jan Henning Klusmann
    Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany
    Blood 111:2991-8. 2008
  9. ncbi Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
    Jean-Pierre Bourquin
    Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:3339-44. 2006
  10. ncbi Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome
    Claudia Langebrake
    Medizinische Hochschule Hannover, Department of Pediatric Hematology and Oncology, Carl Neuberg Strasse 1, 30625 Hannover
    Haematologica 91:1473-80. 2006

Collaborators

Detail Information

Publications11

  1. ncbi Minimising the long-term adverse effects of childhood leukaemia therapy
    Claudia Langebrake
    Department of Paediatric Haematology and Oncology, University Children s Hospital Munster, Munster, Germany
    Drug Saf 25:1057-77. 2002
    ..Future approaches to predict severe toxicity may be based upon pharmacogenetics and gene profiling...
  2. ncbi Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring
    Claudia Langebrake
    Department of Pediatric Hematology and Oncology, University Children s Hospital Munster, Munster, Germany
    Cytometry B Clin Cytom 63:1-9. 2005
    ....
  3. ncbi Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts
    C Langebrake
    University Children s Hospital Muenster, Department of Pediatric Hematology and Oncology, 48129 Muenster
    Klin Padiatr 217:126-34. 2005
    ..The blast cells of both entities show megakaryoblastic/erythroblastic features (M7/M6) and cannot be distinguished by morphological characteristics...
  4. ncbi Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11)
    J Neudenberger
    Department of Paediatric Haematology and Oncology, University Children's Hospital Muenster, Muenster, Germany
    Br J Haematol 133:337-44. 2006
    ..Thus, NG2 appears to be upregulated with differentiation and not to be expressed on primitive disease-maintaining cells. This hampers the clinical use of NG2 as a therapeutic target and as a sensitive marker for MRD detection...
  5. ncbi [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study]
    D Reinhardt
    Pädiatrische Hämatologie Onkologie, Universitat Munster, Germany
    Klin Padiatr 214:179-87. 2002
    ..However, the impact on treatment stratification is not established. The AML-BFM 98 MRD study started in 1/2000 in order to evaluate, standardize and establish immunophenotyping in AML in children...
  6. ncbi Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group
    Claudia Langebrake
    Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
    J Clin Oncol 24:3686-92. 2006
    ..However, the optimal time points for investigation, the best antibody combinations, and most importantly, the clinical impact of RD analysis remain unclear...
  7. ncbi Preanalytical mRNA stabilization of whole bone marrow samples
    Claudia Langebrake
    Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
    Clin Chem 53:587-93. 2007
    ....
  8. ncbi Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
    Jan Henning Klusmann
    Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover, Germany
    Blood 111:2991-8. 2008
    ..A history of TL may therefore define a lower-risk ML-DS subgroup. This study was registered at www.clinicaltrials.gov as no. NCT 00111345...
  9. ncbi Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
    Jean-Pierre Bourquin
    Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:3339-44. 2006
    ..Our results identify relevant signatures for distinct AMKL entities and provide insight into gene expression changes associated with these related leukemias...
  10. ncbi Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome
    Claudia Langebrake
    Medizinische Hochschule Hannover, Department of Pediatric Hematology and Oncology, Carl Neuberg Strasse 1, 30625 Hannover
    Haematologica 91:1473-80. 2006
    ..g. expression of the truncated GATA1s), which are different from those of non-DS childhood acute myeloid leukemias (AML). The objective of this study was to investigate factors predisposing to the development of ML-DS...
  11. ncbi Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression
    Stefan Gattenloehner
    Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
    Blood 110:2027-33. 2007
    ..These findings indicate the potential for new therapy of CD56(high) AML by suppression of the "overactive" RUNX1/CD56/NF-kappaB signaling pathway(s)...